Safety and dose modification for patients receiving niraparib

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.4K citations · Full text

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Cancer Management, Gynecology +7

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Rucaparib Maintenance Treatment, Medicine, Recurrent Ovarian Carcinoma +7

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Nuala McCabe, Nicholas C. Turner, Christopher J. Lord et al. · Cancer Research · 2006 · 1.3K citations